Dongzheng Gai

Researcher

UAMS

Faculty Researcher

8 h-index 26 pubs 258 cited

Research Areas

Biomedical Subjects

Links

Lab Website

OverviewAI-generated summary

Dongzheng Gai's research focuses on understanding the molecular mechanisms underlying multiple myeloma and related blood cancers. His work investigates how specific genes and proteins, such as TRIP13, NEK2, and CST6, influence tumor development, progression, and the associated bone disease characteristic of multiple myeloma. Gai has published research on the role of GPR109A in regulating osteoclastogenesis and bone resorption in mice, and how decreased bone resorption can be observed in specific mouse models with altered myeloid cell function. His recent publications also explore the potential of bispecific CAR-T cells targeting BCMA and CD24, as well as BCMA- and CST6-specific CAR T cells, for controlling multiple myeloma growth and suppressing osteolytic lesions in preclinical models. Additionally, Gai has contributed to research identifying gene signatures that can predict the progression of monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma. He has an h-index of 8 and has authored 26 publications with 258 citations.

Metrics

h-index: 8
Publications: 26
Citations: 258

Selected Publications

Cystatin M/E Ameliorates Multiple Myeloma-Induced Hyper Osteolytic Bone Resorption (2025)

Cancers 1 citation DOI OpenAlex
Cystatin M/E ameliorates bone resorption through increasing osteoclastic cell estrogen influx (2024)

Research Square 1 citation DOI OpenAlex
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth (2024)

Nature Communications 46 citations DOI OpenAlex
BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions (2023)

Journal of Clinical Investigation 7 citations DOI OpenAlex
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma (2023)

Cell Reports Medicine 17 citations DOI OpenAlex
P-066 BCMA-CAR-T cells with synthetic circuits of CST6 lyse tumor cells and suppress osteolytic lesions in multiple myeloma (2023)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex
A gene signature can predict risk of MGUS progressing to multiple myeloma (2023)

Journal of Hematology & Oncology 14 citations DOI OpenAlex
Decreased bone resorption in Ezh2 myeloid cell conditional knockout mouse model (2023)

The FASEB Journal 12 citations DOI OpenAlex
A Gene Signature Can Predict Risk of MGUS Progressing to Multiple Myeloma (2023)

SSRN Electronic Journal DOI OpenAlex
A 12 Gene Signature Accurately Predicts Multiple Myeloma Progression from Monoclonal Gammopathy of Undetermined Significance (2022)

Blood DOI OpenAlex
CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation (2022)

Journal of Clinical Investigation 24 citations DOI OpenAlex
Deep-Sequencing Can be Used to Reconstruct and Extend Microarray-Based Classification and Risk Stratification for Multiple Myeloma (2021)

OpenAlex
NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma (2021)

Blood 3 citations DOI OpenAlex
Ezh2 mediates epigenetic regulation of osteoclastogenesis and bone remodeling in mice (2021)

bioRxiv (Cold Spring Harbor Laboratory) 1 citation DOI OpenAlex
GPR109A mediates the effects of hippuric acid on regulating osteoclastogenesis and bone resorption in mice (2021)

Communications Biology 30 citations DOI OpenAlex